The role of anticonvulsants in preventive migraine therapy

Current Pain and Headache Reports

Volumn 7, Issue 1, 2003, Pages 63-66

  Corbo, Jill ^a  

^a JACOBI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIMIGRAINE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLONAZEPAM; FLUNARIZINE; GABAPENTIN; METOPROLOL; NADOLOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIZOTIFEN; PROPRANOLOL; TIMOLOL; TOLFENAMIC ACID; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VERAPAMIL; ACETIC ACID DERIVATIVE; AMINE; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; DRUG DERIVATIVE; FRUCTOSE;

ALOPECIA; ANOREXIA; ANTICONVULSANT THERAPY; BODY WEIGHT DISORDER; CLINICAL TRIAL; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG USE; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GABAERGIC TRANSMISSION; HAIR LOSS; HUMAN; LIVER TOXICITY; MIGRAINE; PARESTHESIA; PATHOPHYSIOLOGY; REVIEW; SOMNOLENCE; TASTE DISORDER; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; TREMOR; COMPARATIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ACETIC ACIDS; AMINES; ANTICONVULSANTS; CLINICAL TRIALS; CYCLOHEXANECARBOXYLIC ACIDS; DRUG APPROVAL; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MIGRAINE DISORDERS; RECURRENCE; TREATMENT OUTCOME; VALPROIC ACID;

EID: 0037315352     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-003-0012-6     Document Type: Review

References (26)

1. Lipton RB, Stewart WF, Diamond S, et al.: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001, 41:646-657.
2. Collins JG: Prevalence of selected chronic conditions in the United States. Vital Health Statistics 1986, 10:1-66.
3. Ramadan NM, Silberstein SD, Freitag FG, et al.: Evidence-Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management for Prevention of Migraine. Neurology (serial online), http://www.neurology.org. Accessed on August 12, 2002.
4. Morey SS: Guidelines of migraine, part 4: general principles of preventive therapy. Am Fam Physician 2000, 62:2359-2363.
5. Koehler PJ, Bruyn GW: Migraine treatment in the Netherlands in the early 20th century. Ned Tijdschr Geneeskd 1988, 142:2009-2013.
6. Depakote ER: Migraine study group: a randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002, 58:1652-1659.
7. Loscher W: Valproate induced changes in GABA metabolism at the subcellular level. Bichem Pharmacol 1981, 30:1364-1366.
8. Bloom FE: Neurohumoral transmission and the central nervous system. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, edn 8. Edited by Gilman AG, Rall TW, Nies AS, Taylor P. New York: McGraw-Hill; 1990:244-268.
9. Cutrer FM, Silberstein SD, Mathew NT, Rozen TD: Antiepileptic drugs in migraine, cluster headache, and mood disorders. Headache 2001, 41(suppl 1):S1-S32.
10. Magnus L: Nonepileptic uses of gabapentin. Epilepsia 1999, 40(suppl 6):566-572.
11. Cutrer FM: Antiepileptic drugs: how they work in headache. Headache 2001, 41(suppl 1):S3-S10.
12. Mathew NT: Antiepileptic drugs in migraine prevention. Headache 2001, 41(suppl 1):518-524.
13. Sorenson KV: Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988, 78:346-348.
14. Hering R, Kuritzky A: Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992, 12:81-84.
15. Jensen R, Brinck T, Olesen J: Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994, 44:647-651.
16. Mathew NT, Saper JR, Silberstein SD, et al.: Migraine prophylaxis with divalproex. Arch Neurol 1995, 52:281-286.
17. Klapper J: Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997, 17:103-108.
18. Kinze S, Clauss M, Reuter U, et al.: Valproic acid is effective in migraine prophylaxis at low serum levels: a prospective open-label study. Headache 2001, 41:774-778.
19. Tfelt-Hansen P: Prophylactic pharmacotherapy of migraine: some practical guidelines. Neurol Clin 1997, 15:153-165.
20. Silberstein SD, Collins SD: Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache 1999, 39:633-643.
21. Rompel H, Bauermeister PW: Etiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. S Afr Med J 1970, 44:75-80.
22. Stensrud P, Sjaastad O: Clonazepam (rivotril) in migraine prophylaxis. Headache 1979, 19:333-334.
23. Wessely P, Baumgarrtner C, Klingler D, et al.: Preliminary results of a double-blind study with the new migraine prophylactic drug Gabapentin. Cephalalgia 1987, 7(suppl 6):477-478.
24. Mathew NT, Rapoport A, Saper J, et al.: Efficacy of gabapentin in migraine prophylaxis. Headache 2001, 41:119-128.
25. Storey JR, Calder CS, Hart DE, Potter DL: Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001, 41:968-975.
26. Edwards KR, Glantz MJ, Shea P, et al.: Topiramate for migraine prophylaxis: a double-blind, randomized, placebo-controlled study (abstract). Headache 2000, 40:4607.